Optherion, Inc. is a pioneering biotechnology company dedicated to the advancement of diagnostic tools and disease-modifying therapeutics aimed at effectively managing and treating early-stage age-related macular degeneration (AMD), dense deposit disease (DDD, also known as membranoproliferative glomerulonephritis [MPGN II]), atypical hemolytic uremic syndrome (aHUS), and other chronic diseases associated with the alternative complement cascade.
The core of Optherion’s intellectual property is founded on recent breakthroughs in scientific research that have identified specific genes linked to AMD and various renal diseases. AMD, prevalent among individuals over the age of 60 in developed countries, stands as the primary cause of blindness. It is estimated that approximately 15-20 million individuals in the U.S. and more than 50 million worldwide are affected by AMD. Additionally, DDD and aHUS, rare renal conditions primarily affecting young individuals, often progress to end-stage renal disease.
The notable scientific discoveries published in 2005 have established an association between Complement Factor H (CFH) and Complement Factor B (CFB)/Complement Component 2 (C2) – both regulators of the alternative complement pathway – and AMD and DDD. Subsequently, the identification of genetic variations on Chromosome 10 and a limited set of other genes has further reinforced Optherion’s diagnostic and therapeutic developmental initiatives.
Headquartered in New Haven, Connecticut, USA, Optherion operates from the biotechnology campus of the University of Iowa in Coralville, Iowa, USA, underscoring its commitment to cutting-edge research and innovation.